Sotera Health (NASDAQ:SHC) Releases FY 2024 Earnings Guidance

Sotera Health (NASDAQ:SHC) updated its FY 2024 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.670-0.750 for the period, compared to the consensus estimate of 0.720. The company issued revenue guidance of $1.1 billion-$1.1 billion, compared to the consensus revenue estimate of $1.1 billion.

Sotera Health Stock Performance

NASDAQ:SHC opened at $15.80 on Tuesday. The stock has a fifty day moving average price of $15.95 and a 200-day moving average price of $13.64. The company has a market cap of $4.47 billion, a price-to-earnings ratio of 112.86 and a beta of 2.08. Sotera Health has a fifty-two week low of $10.71 and a fifty-two week high of $17.44. The company has a debt-to-equity ratio of 5.46, a quick ratio of 2.59 and a current ratio of 2.93.

Sotera Health (NASDAQ:SHC) last released its earnings results on Monday, August 5th. The company reported $0.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.15 by $0.04. The business had revenue of $277.00 million for the quarter, compared to analyst estimates of $266.45 million. Sotera Health had a net margin of 3.65% and a return on equity of 47.26%. Sotera Health’s revenue for the quarter was up 8.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.19 earnings per share. As a group, equities analysts anticipate that Sotera Health will post 0.64 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities research analysts have commented on SHC shares. Barclays increased their price objective on shares of Sotera Health from $14.00 to $17.00 and gave the company an “overweight” rating in a research note on Tuesday, August 6th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $17.00 target price on shares of Sotera Health in a report on Tuesday, August 6th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $15.70.

Insiders Place Their Bets

In other Sotera Health news, Director Gtcr Investment Xi Llc sold 10,000,000 shares of the company’s stock in a transaction on Friday, September 6th. The shares were sold at an average price of $15.03, for a total value of $150,300,000.00. Following the completion of the transaction, the director now directly owns 49,215,301 shares in the company, valued at approximately $739,705,974.03. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 55.12% of the company’s stock.

About Sotera Health

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.